<HTML>
<HEAD>
<TITLE>sv8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
</DIV>


<P align="center" style="font-size: 10pt"><B>As filed with the Securities and Exchange Commission on January&nbsp;13, 2005</B>



<DIV align="right" style="font-size: 10pt"><B>Registration No.&nbsp;333-_________</B>
</DIV>


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">




<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 10pt"><B>WASHINGTON, D.C. 20549</B></DIV>



<P align="center" style="font-size: 10pt"><HR size="1" noshade width="26%" align="center" color="#000000">


<P align="center" style="font-size: 18pt"><B>FORM S-8</B>
<DIV align="center" style="font-size: 12pt"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B>


<P align="center" style="font-size: 10pt"><HR size="1" noshade width="26%" align="center" color="#000000">


<P align="center" style="font-size: 24pt"><B>PHARMACYCLICS, INC.</B>


<DIV align="center" style="font-size: 10pt"><B>(Exact Name of Registrant as Specified in Its Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or Other Jurisdiction of<BR>
Incorporation or Organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94-3148201</B><BR>
(IRS Employer<BR>
Identification Number)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>995 East Arques Avenue<BR>
Sunnyvale, California 94085-4521</B><BR>
(Address of Principal Executive Offices including Zip Code)



<P align="center" style="font-size: 10pt"><B>PHARMACYCLICS, INC.<BR>
2004 EQUITY INCENTIVE AWARD PLAN</B><BR>
(Full Title of the Plan)



<P align="center" style="font-size: 10pt"><B>Richard A. Miller, M.D.<BR>
President and Chief Executive Officer<BR>
Pharmacyclics, Inc.<BR>
995 East Arques Avenue<BR>
Sunnyvale, California 94085-4521<BR>
(408)&nbsp;774-0330</B><BR>
(Name and Address and Telephone Number,<BR>
Including Area Code, of Agent for Service)



<P align="center" style="font-size: 10pt"><B>CALCULATION OF REGISTRATION FEE</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-bottom: 3px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>Title of Each Class of</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Proposed Maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Proposed Maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amount of</B></TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>Securities to be</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>to be</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Offering Price Per</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Aggregate Offering</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Registration</B></TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center" style="border-bottom: 0px solid #000000"><B>Registered</B></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Registered(1)</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Share (2)</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Price (2)</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Fee (3)</B></TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">
    <DIV style="margin-left:15px; text-indent:-0px">Common Stock, par value $0.0001 per
share issuable pursuant to the
Pharmacyclics, Inc. 2004 Equity
Incentive Award Plan</DIV></TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="center" style="border-top: 1px solid #000000">5,457,480</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="center" style="border-top: 1px solid #000000">$10.565</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="center" style="border-top: 1px solid #000000">$57,658,276.20</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="center" style="border-top: 1px solid #000000">$5,805.13</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-top: 3px solid #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Shares to be offered and sold under the
Pharmacyclics, Inc. (the &#147;Company&#148;), 2004 Equity
Incentive Award Plan (the &#147;2004 Plan&#148;) comprise: (i)&nbsp;600,000 shares not previously registered; (ii)
727,353 shares previously registered for issuance under the Pharmacyclics, Inc, 1995 Stock Option
Plan (the &#147;1995 Plan&#148;) on February&nbsp;14, 2001 (Registration No.&nbsp;333-55592), 61,750 shares previously
registered for issuance under the Pharmacyclics, Inc. Non-Employee Directors Stock Option Plan
(together with the 1995 Plan, the &#147;Prior Plans&#148;) on February&nbsp;14, 2001 (Registration No.&nbsp;333-55592)
and on January&nbsp;31, 2002 (Registration No.&nbsp;333-81870), in each case, that may no longer be issued
under the Prior Plans and that may be offered and sold under the 2004 Plan; and (iii)&nbsp;4,068,377
shares subject to awards previously granted under the Prior Plans that may be cancelled or are
subject to cancellation and upon cancellation will be available for issuance under the 2004 Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD width="1%" nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Estimated solely for the purposes of calculating the registration fee pursuant to
Rule 457(h) and (c)&nbsp;under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and is
based on the average of the high and low sales price of the Common Stock, as reported on the Nasdaq
National Market on January&nbsp;6, 2005 for the 5,457,480 shares issuable under the 2004 Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD width="1%" nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">In accordance with Rule 457(p) of the Securities Act, the aggregate total dollar
amount of the Registration Fee is being offset by the dollar amount of registration fees previously
paid in respect of unissued shares previously registered by the Company on Form S-8, which unissued
shares have been deregistered. The Company has filed a post-effective amendment to its Form S-8
Registration Statement File No.&nbsp;333-55592 and a post-effective amendment to its Form S-8
Registration Statement File No.&nbsp;333-81870, to deregister shares of the Company&#146;s common stock that
are not subject to outstanding option grants under its Prior Plans. The Amount of Registration Fee
was calculated as the difference between the aggregate registration fee of $6,786.38 (calculated
based on the number of shares set forth in subsections (i), (ii)&nbsp;and (iii)&nbsp;of footnote (1), above)
less the sum of $981.25; which includes: (i)&nbsp;the $966.64 portion of the registration fee associated
with 777,353 deregistered shares (727,353 of which were initially registered under the 1995 Plan
and 50,000 of which were initially registered under the Non-Employee Directors Stock Option Plan)
that was previously paid in connection with the Form S-8 Registration Statement File No.&nbsp;333-55592,
filed on February&nbsp;14, 2001 and (ii)&nbsp;the $14.61 registration fee associated with 11,750 deregistered
shares (which were initially registered under the Non-Employee Directors Stock Option Plan) that
was previously paid in connection with the Form S-8 Registration Statement File No.&nbsp;333-81870,
filed on January&nbsp;31, 2002.</TD>
</TR>

</TABLE>



<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PART I<BR> INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">PART II<BR> INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#002">Item&nbsp;3. Incorporation of Documents by Reference.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#003">Item&nbsp;4. Description of Securities.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">Item&nbsp;5. Interests of Named Experts and Counsel.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#005">Item&nbsp;6. Indemnification of Directors and Officers.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">Item&nbsp;7. Exemption from Registration Claimed.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#007">Item&nbsp;8. Exhibits.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#008">Item&nbsp;9. Undertakings.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#010">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="f04631exv5w1.txt">EXHIBIT 5.1</A></TD></TR>
<TR><TD colspan="9"><A HREF="f04631exv23w1.txt">EXHIBIT 23.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "PART I<BR> INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART I<BR>
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information called for in Part&nbsp;I of Form S-8 is not being filed with or included in this
Registration Statement on Form S-8 (by incorporation, by reference or otherwise) in accordance with
the rules and regulations of the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;).

<!-- link1 "PART II<BR> INFORMATION REQUIRED IN THE REGISTRATION STATEMENT" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART II<BR>
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>


<!-- link2 "Item&nbsp;3. Incorporation of Documents by Reference." -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;3. Incorporation of Documents by Reference.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following documents filed by Pharmacyclics, Inc. (the
&#147;Registrant&#148; or &#147;Company&#148;) with the Commission are incorporated herein by
reference:



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
Registrant&#146;s Annual Report on Form 10-K for the fiscal year ended June&nbsp;30,
2004;



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ending September
30, 2004;



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) All other reports filed by the Registrant pursuant to Sections 13(a) and 15(d)
of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;) (other
than information contained in Current Reports on Form 8-K that is deemed
furnished and not filed), since the fiscal year covered by the annual report
referred to in (a) above; and

<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)
The description of Registrant&#146;s common stock contained in its registration
statement on Form 8-A filed with the Commission on October&nbsp;20, 1995, including any amendment or
report filed for the purpose of updating that description, and the description of Registrant&#146;s
Series&nbsp;A junior participating preferred stock contained in our registration statement on Form
8-A filed with the Commission May&nbsp;21, 2002, including any amendment or report filed for the
purpose of updating that description.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, all documents filed by the Registrant pursuant to Section&nbsp;13(a), 13(c), 14
or 15(d) of the Exchange Act after the date of this registration statement and prior to the filing
of a post-effective amendment which indicates that all securities offered have been sold or which
deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference
in this registration statement and to be a part of it from the respective dates of filing such
documents. Any statement contained in a document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of this registration
statement to the extent that a statement contained herein or in any other subsequently filed
document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this registration statement.

<!-- link2 "Item&nbsp;4. Description of Securities." -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;4. Description of Securities.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;5. Interests of Named Experts and Counsel." -->
<DIV align="left"><A NAME="004"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;5. Interests of Named Experts and Counsel.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;6. Indemnification of Directors and Officers." -->
<DIV align="left"><A NAME="005"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;6. Indemnification of Directors and Officers.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Section&nbsp;145 of the Delaware General Corporation Law, the Registrant has broad powers to
indemnify its directors and officers against liabilities they may incur in such capacities,
including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). The
Registrant&#146;s Bylaws (the &#147;Bylaws&#148;) provide that the Registrant shall indemnify its directors and
officers if such officer or director acted (i)&nbsp;in good faith, (ii)&nbsp;in a manner reasonably believed
to be in or not opposed to the best interests of the Registrant, and (iii)&nbsp;with respect to any


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">criminal action or proceeding, had no reasonable cause to believe such conduct was unlawful.
The Registrant believes that indemnification under its Bylaws covers at least negligence and gross
negligence, and requires the Registrant to advance litigation expenses in the case of stockholder
derivative actions or other actions, against an undertaking by the directors and officers to repay
such advances if it is ultimately determined that the director is not entitled to indemnification.
The Bylaws further provide that rights conferred under such Bylaws shall not be deemed to be
exclusive of any other right such persons may have or acquire under any agreement, vote of
stockholders or disinterested directors, or otherwise.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the Registrant&#146;s Certificate of Incorporation (the &#147;Certificate of
Incorporation&#148;) provides that, pursuant to Delaware law, none of its directors shall be liable for
monetary damages for breach of his or her fiduciary duty of care to the Registrant and its
stockholders. This provision in the Certificate of Incorporation does not eliminate the duty of
care, and in appropriate circumstances equitable remedies such as injunctive or other forms of
non-monetary relief will remain available under Delaware law. In addition, each director will
continue to be subject to liability for breach of the director&#146;s duty of loyalty to the Registrant
for acts or omissions not in good faith or involving intentional misconduct, for knowing violations
of law, for actions leading to improper personal benefit to the director, and for payment of
dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The
provision also does not affect a director&#146;s responsibilities under any other law, such as the
federal securities laws or state or federal environmental laws. The Certificate of Incorporation
further provides that the Registrant shall indemnify its directors and officers to the fullest
extent permitted by law and requires the Registrant to advance litigation expenses in the case of
stockholder derivative actions or other actions, against an undertaking by the director to repay
such advances if it is ultimately determined that the director is not entitled to indemnification.
The Certificate of Incorporation also provides that rights conferred under such Certificate of
Incorporation shall not be deemed to be exclusive of any other right such persons may have or
acquire under any statute, the Certificate of Incorporation, the Bylaws, agreement, vote of
stockholders or disinterested directors, or otherwise.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant has obtained a liability insurance policy for the officers and directors that,
subject to certain limitations, terms and conditions, will insure them against losses arising from
wrongful acts (as defined by the policy) in their capacity as directors or officers.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the Registrant has entered into agreements to indemnify its directors and certain
of its officers in addition to the indemnification provided for in the Certificate of Incorporation
and Bylaws. These agreements, among other things, indemnify the Registrant&#146;s directors and certain
of its officers for certain expenses (including attorneys fees), judgments, fines and settlement
amounts incurred by such person in any action or proceeding, including any action by or in the
right of the Registrant, on account of services as a director or officer of the Registrant or as a
director or officer of any subsidiary of the Registrant, or as a director or officer of any other
company or enterprise that the person provides services to at the request of the Registrant.

<!-- link2 "Item&nbsp;7. Exemption from Registration Claimed." -->
<DIV align="left"><A NAME="006"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7. Exemption from Registration Claimed.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;8. Exhibits." -->
<DIV align="left"><A NAME="007"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8. Exhibits.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See the Index to Exhibits on Page 6.

<!-- link2 "Item&nbsp;9. Undertakings." -->
<DIV align="left"><A NAME="008"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9. Undertakings.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The undersigned Company hereby undertakes:



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:



<P align="left" style="margin-left:6%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act;



<P align="left" style="margin-left:6%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to reflect in the prospectus any facts or events arising after the
effective date of this Registration Statement (or the most recent
post-effective amendment thereof) which,


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt">individually or in the aggregate, represent a fundamental change in the
information set forth in this Registration Statement. Notwithstanding the
foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with
the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than a 20&nbsp;percent change in the maximum
aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148;
table in the effective Registration Statement; and



<P align="left" style="margin-left:6%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) to include any material information with respect to the plan of
distribution not previously disclosed in this Registration Statement or any
material change to such information in this Registration Statement.



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The Company hereby undertakes that, for the purposes of determining any
liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of
the securities being registered which remain unsold at the termination of the
offering.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;That, for purposes of determining any liability under the Securities Act, each
filing of the Company&#146;s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act
that is incorporated by reference in this Registration Statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the Company pursuant to the
foregoing provisions, or otherwise, the Company has been advised that in the opinion of the
Commission such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Company of expenses incurred or paid by a
director, officer or controlling person of the Company in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Company will, unless in the opinion of
its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of
such issue.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="009"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Sunnyvale, State of California, on January&nbsp;13, 2005.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Pharmacyclics, Inc.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Richard A. Miller
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Richard A. Miller, M.D., President and Chief&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose signature appears below constitutes and appoints Richard A. Miller, M.D. and
Leiv Lea, and each of them, his true and lawful attorneys-in-fact and agents, each with full power
of substitution and resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments) to this
Registration Statement, and to file the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in order to effectuate the same as fully, to
all intents and purposes, as he might or could do in person, hereby ratifying and confirming all
that each of said attorneys-in-fact and agents, or either of them, may lawfully do or cause to be
done by virtue hereof.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this registration statement has
been signed by the following persons in the capacities indicated on the dates indicated:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Title</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" nowrap valign="top"><DIV style="margin-left:15px; text-indent:-15px">/s/ Richard A. Miller
<HR size="1" noshade color="#000000">
Richard A. Miller, M.D.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
President and Chief Executive Officer and
Director
(Principal Executive Officer)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13, 2005</TD>
</TR>
<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/ Leiv Lea
<HR size="1" noshade color="#000000">
Leiv Lea</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Chief Financial Officer and Secretary
(Principal Accounting Officer)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13, 2005</TD>
</TR>
<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/ Miles R. Gilburne
<HR size="1" noshade color="#000000">
Miles R. Gilburne</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13, 2005</TD>
</TR>
<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/ Loretta M. Itri
<HR size="1" noshade color="#000000">
Loretta M. Itri, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13 , 2005</TD>
</TR>
<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/ Richard M. Levy
<HR size="1" noshade color="#000000">
Richard M. Levy, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13, 2005</TD>
</TR>
<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/ William R. Rohn
<HR size="1" noshade color="#000000">
William R. Rohn</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13, 2005</TD>
</TR>
<TR valign="bottom" style="padding-top: 1em">
    <TD align="center" nowrap valign="top">/s/ Craig C. Taylor
<HR size="1" noshade color="#000000">
Craig C. Taylor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January 13, 2005</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="010"></A></DIV>

<P align="center" style="font-size: 10pt"><B>INDEX TO EXHIBITS</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pharmacyclics, Inc. 2004 Equity Incentive Award Plan (1)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion as to the legality of the securities being registered</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Latham &#038; Watkins LLP (included in Exhibit&nbsp;5.1 hereto)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney (included in the signature page hereto)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P>
<HR size="1" width="18%" align="left" noshade color="#000000">

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Incorporated by reference to Exhibit&nbsp;B of the Registrant&#146;s Proxy Statement Pursuant to
Section 14(a) filed with the Commission on October&nbsp;26, 2004.</TD>
</TR>

</TABLE>




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "f04631sv8.htm", "description": "FORM S-8", "secsgml_size_bytes": 38410}]
{"company-data": {"conformed-name": "PHARMACYCLICS INC", "cik": "0000949699", "assigned-sic": "2834", "irs-number": "943148201", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-122035", "film-number": "05528874"}, "business-address": {"street1": "PHARMACYCLICS INC", "street2": "995 E ARQUES AVE", "city": "SUNNYVALE", "state": "CA", "zip": "94085-4521", "phone": "408 774 0330"}, "mail-address": {"street1": "PHARMACYCLICS INC", "street2": "995 E ARQUES AVE", "city": "SUNNYVALE", "state": "CA", "zip": "94085-4521"}}
sv8
Table of Contents
As filed with the Securities and Exchange Commission on January 13, 2005
Registration No. 333-_________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PHARMACYCLICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
94-3148201
(IRS Employer
Identification Number)
995 East Arques Avenue
Sunnyvale, California 94085-4521
(Address of Principal Executive Offices including Zip Code)
PHARMACYCLICS, INC.
2004 EQUITY INCENTIVE AWARD PLAN
(Full Title of the Plan)
Richard A. Miller, M.D.
President and Chief Executive Officer
Pharmacyclics, Inc.
995 East Arques Avenue
Sunnyvale, California 94085-4521
(408) 774-0330
(Name and Address and Telephone Number,
Including Area Code, of Agent for Service)
CALCULATION OF REGISTRATION FEE
Title of Each Class of
Amount
Proposed Maximum
Proposed Maximum
Amount of
Securities to be
to be
Offering Price Per
Aggregate Offering
Registration
Registered
Registered(1)
Share (2)
Price (2)
Fee (3)
Common Stock, par value $0.0001 per
share issuable pursuant to the
Pharmacyclics, Inc. 2004 Equity
Incentive Award Plan
5,457,480
$10.565
$57,658,276.20
$5,805.13
(1)
Shares to be offered and sold under the
Pharmacyclics, Inc. (the "Company"), 2004 Equity
Incentive Award Plan (the "2004 Plan") comprise: (i) 600,000 shares not previously registered; (ii)
727,353 shares previously registered for issuance under the Pharmacyclics, Inc, 1995 Stock Option
Plan (the "1995 Plan") on February 14, 2001 (Registration No. 333-55592), 61,750 shares previously
registered for issuance under the Pharmacyclics, Inc. Non-Employee Directors Stock Option Plan
(together with the 1995 Plan, the "Prior Plans") on February 14, 2001 (Registration No. 333-55592)
and on January 31, 2002 (Registration No. 333-81870), in each case, that may no longer be issued
under the Prior Plans and that may be offered and sold under the 2004 Plan; and (iii) 4,068,377
shares subject to awards previously granted under the Prior Plans that may be cancelled or are
subject to cancellation and upon cancellation will be available for issuance under the 2004 Plan.
(2)
Estimated solely for the purposes of calculating the registration fee pursuant to
Rule 457(h) and (c) under the Securities Act of 1933, as amended (the "Securities Act"), and is
based on the average of the high and low sales price of the Common Stock, as reported on the Nasdaq
National Market on January 6, 2005 for the 5,457,480 shares issuable under the 2004 Plan.
(3)
In accordance with Rule 457(p) of the Securities Act, the aggregate total dollar
amount of the Registration Fee is being offset by the dollar amount of registration fees previously
paid in respect of unissued shares previously registered by the Company on Form S-8, which unissued
shares have been deregistered. The Company has filed a post-effective amendment to its Form S-8
Registration Statement File No. 333-55592 and a post-effective amendment to its Form S-8
Registration Statement File No. 333-81870, to deregister shares of the Company's common stock that
are not subject to outstanding option grants under its Prior Plans. The Amount of Registration Fee
was calculated as the difference between the aggregate registration fee of $6,786.38 (calculated
based on the number of shares set forth in subsections (i), (ii) and (iii) of footnote (1), above)
less the sum of $981.25; which includes: (i) the $966.64 portion of the registration fee associated
with 777,353 deregistered shares (727,353 of which were initially registered under the 1995 Plan
and 50,000 of which were initially registered under the Non-Employee Directors Stock Option Plan)
that was previously paid in connection with the Form S-8 Registration Statement File No. 333-55592,
filed on February 14, 2001 and (ii) the $14.61 registration fee associated with 11,750 deregistered
shares (which were initially registered under the Non-Employee Directors Stock Option Plan) that
was previously paid in connection with the Form S-8 Registration Statement File No. 333-81870,
filed on January 31, 2002.
TABLE OF CONTENTS
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
Item 4. Description of Securities.
Item 5. Interests of Named Experts and Counsel.
Item 6. Indemnification of Directors and Officers.
Item 7. Exemption from Registration Claimed.
Item 8. Exhibits.
Item 9. Undertakings.
SIGNATURES
INDEX TO EXHIBITS
EXHIBIT 5.1
EXHIBIT 23.1
Table of Contents
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information called for in Part I of Form S-8 is not being filed with or included in this
Registration Statement on Form S-8 (by incorporation, by reference or otherwise) in accordance with
the rules and regulations of the Securities and Exchange Commission (the "
Commission
").
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The
following documents filed by Pharmacyclics, Inc. (the
"Registrant" or "Company") with the Commission are incorporated herein by
reference:
(a)
Registrant's Annual Report on Form 10-K for the fiscal year ended June 30,
2004;
(b) Registrant's Quarterly Report on Form 10-Q for the quarter ending September
30, 2004;
(c) All other reports filed by the Registrant pursuant to Sections 13(a) and 15(d)
of the Securities Exchange Act of 1934, as amended (the
"Exchange Act") (other
than information contained in Current Reports on Form 8-K that is deemed
furnished and not filed), since the fiscal year covered by the annual report
referred to in (a) above; and
(d)
The description of Registrant's common stock contained in its registration
statement on Form 8-A filed with the Commission on October 20, 1995, including any amendment or
report filed for the purpose of updating that description, and the description of Registrant's
Series A junior participating preferred stock contained in our registration statement on Form
8-A filed with the Commission May 21, 2002, including any amendment or report filed for the
purpose of updating that description.
In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14
or 15(d) of the Exchange Act after the date of this registration statement and prior to the filing
of a post-effective amendment which indicates that all securities offered have been sold or which
deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference
in this registration statement and to be a part of it from the respective dates of filing such
documents. Any statement contained in a document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of this registration
statement to the extent that a statement contained herein or in any other subsequently filed
document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this registration statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Under Section 145 of the Delaware General Corporation Law, the Registrant has broad powers to
indemnify its directors and officers against liabilities they may incur in such capacities,
including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). The
Registrant's Bylaws (the "Bylaws") provide that the Registrant shall indemnify its directors and
officers if such officer or director acted (i) in good faith, (ii) in a manner reasonably believed
to be in or not opposed to the best interests of the Registrant, and (iii) with respect to any
Table of Contents
criminal action or proceeding, had no reasonable cause to believe such conduct was unlawful.
The Registrant believes that indemnification under its Bylaws covers at least negligence and gross
negligence, and requires the Registrant to advance litigation expenses in the case of stockholder
derivative actions or other actions, against an undertaking by the directors and officers to repay
such advances if it is ultimately determined that the director is not entitled to indemnification.
The Bylaws further provide that rights conferred under such Bylaws shall not be deemed to be
exclusive of any other right such persons may have or acquire under any agreement, vote of
stockholders or disinterested directors, or otherwise.
In addition, the Registrant's Certificate of Incorporation (the "Certificate of
Incorporation") provides that, pursuant to Delaware law, none of its directors shall be liable for
monetary damages for breach of his or her fiduciary duty of care to the Registrant and its
stockholders. This provision in the Certificate of Incorporation does not eliminate the duty of
care, and in appropriate circumstances equitable remedies such as injunctive or other forms of
non-monetary relief will remain available under Delaware law. In addition, each director will
continue to be subject to liability for breach of the director's duty of loyalty to the Registrant
for acts or omissions not in good faith or involving intentional misconduct, for knowing violations
of law, for actions leading to improper personal benefit to the director, and for payment of
dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The
provision also does not affect a director's responsibilities under any other law, such as the
federal securities laws or state or federal environmental laws. The Certificate of Incorporation
further provides that the Registrant shall indemnify its directors and officers to the fullest
extent permitted by law and requires the Registrant to advance litigation expenses in the case of
stockholder derivative actions or other actions, against an undertaking by the director to repay
such advances if it is ultimately determined that the director is not entitled to indemnification.
The Certificate of Incorporation also provides that rights conferred under such Certificate of
Incorporation shall not be deemed to be exclusive of any other right such persons may have or
acquire under any statute, the Certificate of Incorporation, the Bylaws, agreement, vote of
stockholders or disinterested directors, or otherwise.
The Registrant has obtained a liability insurance policy for the officers and directors that,
subject to certain limitations, terms and conditions, will insure them against losses arising from
wrongful acts (as defined by the policy) in their capacity as directors or officers.
In addition, the Registrant has entered into agreements to indemnify its directors and certain
of its officers in addition to the indemnification provided for in the Certificate of Incorporation
and Bylaws. These agreements, among other things, indemnify the Registrant's directors and certain
of its officers for certain expenses (including attorneys fees), judgments, fines and settlement
amounts incurred by such person in any action or proceeding, including any action by or in the
right of the Registrant, on account of services as a director or officer of the Registrant or as a
director or officer of any subsidiary of the Registrant, or as a director or officer of any other
company or enterprise that the person provides services to at the request of the Registrant.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
See the Index to Exhibits on Page 6.
Item 9. Undertakings.
(a) The undersigned Company hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or events arising after the
effective date of this Registration Statement (or the most recent
post-effective amendment thereof) which,
Table of Contents
individually or in the aggregate, represent a fundamental change in the
information set forth in this Registration Statement. Notwithstanding the
foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with
the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than a 20 percent change in the maximum
aggregate offering price set forth in the "Calculation of Registration Fee"
table in the effective Registration Statement; and
(iii) to include any material information with respect to the plan of
distribution not previously disclosed in this Registration Statement or any
material change to such information in this Registration Statement.
(2) The Company hereby undertakes that, for the purposes of determining any
liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of
the securities being registered which remain unsold at the termination of the
offering.
(b) That, for purposes of determining any liability under the Securities Act, each
filing of the Company's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act
that is incorporated by reference in this Registration Statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the Company pursuant to the
foregoing provisions, or otherwise, the Company has been advised that in the opinion of the
Commission such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Company of expenses incurred or paid by a
director, officer or controlling person of the Company in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Company will, unless in the opinion of
its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of
such issue.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Sunnyvale, State of California, on January 13, 2005.
Pharmacyclics, Inc.
/s/ Richard A. Miller
Richard A. Miller, M.D., President and Chief
Executive Officer
Each person whose signature appears below constitutes and appoints Richard A. Miller, M.D. and
Leiv Lea, and each of them, his true and lawful attorneys-in-fact and agents, each with full power
of substitution and resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments) to this
Registration Statement, and to file the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in order to effectuate the same as fully, to
all intents and purposes, as he might or could do in person, hereby ratifying and confirming all
that each of said attorneys-in-fact and agents, or either of them, may lawfully do or cause to be
done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has
been signed by the following persons in the capacities indicated on the dates indicated:
Signature
Title
Date
/s/ Richard A. Miller
Richard A. Miller, M.D.
President and Chief Executive Officer and
Director
(Principal Executive Officer)
January 13, 2005
/s/ Leiv Lea
Leiv Lea
Chief Financial Officer and Secretary
(Principal Accounting Officer)
January 13, 2005
/s/ Miles R. Gilburne
Miles R. Gilburne
Director
January 13, 2005
/s/ Loretta M. Itri
Loretta M. Itri, M.D.
Director
January 13 , 2005
/s/ Richard M. Levy
Richard M. Levy, Ph.D.
Director
January 13, 2005
/s/ William R. Rohn
William R. Rohn
Director
January 13, 2005
/s/ Craig C. Taylor
Craig C. Taylor
Director
January 13, 2005
Table of Contents
INDEX TO EXHIBITS
Exhibit
No.
Description
4.1
Pharmacyclics, Inc. 2004 Equity Incentive Award Plan (1)
5.1
Opinion as to the legality of the securities being registered
23.1
Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm
23.2
Consent of Latham & Watkins LLP (included in Exhibit 5.1 hereto)
24.1
Power of Attorney (included in the signature page hereto)
(1)
Incorporated by reference to Exhibit B of the Registrant's Proxy Statement Pursuant to
Section 14(a) filed with the Commission on October 26, 2004.